Bone loss occurs less often when people on failing antiretroviral therapy switch to a NRTI-sparing second-line regimen containing raltegravir, researchers reported last week at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.

This sub-analysis from the SECOND-LINE study was one of several looking at bone loss and its relation to HIV infection and its treatment. Jennifer Hoy from Alfred Hospital in Melbourne gave an overview of her team's findings at a press conference prior to her late-breaker presentation.